Register to get free articles
Want unlimited access? View Plans
Already have an account? Sign in
Calculus has announced the appointment of Elizabeth Klein as investment director.
Klein will help lead Calculus with its strategy to build diversified portfolios, utilising her network and relationships to generate deal flow, predominantly in the life sciences sector.
Klein joins from Klein-Edmonds Associates, which she founded in 2015. Her career spans equity research and investment analysis, and her client base includes Radnor Capital Partners, Grant Thornton, and the Bio-Industry Association.
Commenting on the appointment, John Glencross, CEO and founder of Calculus, said: “It’s a real coup to have someone of Elizabeth’s expertise and reputation join Calculus at such a pivotal time for the industry.
“Her breadth of knowledge, agility, and impressive network will undoubtedly be a key factor to our success in the coming months as we strive to help smaller, entrepreneurial growth companies scale-up, as well as creating value for our investors.”
He added: “While the current economic climate remains broadly uncertain, the recent endorsement of the sector from the government will enable Venture Capital Trusts (VCTs) and Enterprise Investment Schemes (EISs) to remain as one of the most tax efficient, attractive solutions for those wishing to invest in UK businesses.”
Elizabeth Klein said: “I am delighted to be joining Calculus at such an exciting time in the firm’s development. In recent months, the firm has launched a series of new and competitive VCT and EIS offers to clients. This, coupled with the government’s stamp of approval for the continuation of the schemes, will mean a very busy time ahead for the company. I’m really looking forward to working with the team.”
